Aidport Sp. z o.o.

Research site

Poland Ul Ksiedza Stanisława Kozierowskiego 24, 60-185 Skorzewo, Poland

38 trials recruiting
Chronic lymphocytic leukaemia · Diffuse large B-cell lymphoma · Myelofibrosis
Adult patients

About Specializations

Aidport Sp. z o.o. in Skorzewo, Poland specialises in clinical trials of conditions such as Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma, Myelofibrosis, Follicular lymphoma, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Ul Ksiedza Stanisława Kozierowskiego 2460-185 SkorzewoPoland

Open in maps ↗

Recruiting now: 38 trials
Conditions studied: 76

More sites in Skorzewo Poland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

74 clinical trials

Bladder transitional cell carcinoma+1

Recruiting

A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

Registered drug

A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Enfortumab Vedotin
Sponsor:Eli Lilly & Co.

Contact Research Centre

Urinary incontinence+1

Recruiting

Orforglipron for stress urinary incontinence in women with obesity or overweight

Investigational

Orforglipron for stress urinary incontinence in women with obesity or overweight

Investigational

Poland

Participants:18–64 years
Sponsor:Eli Lilly & Co.

Contact Research Centre

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Recruiting

Registered drug

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Baxdrostat
Sponsor:AstraZeneca AB

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Budesonide
Sponsor:AstraZeneca AB

Contact Research Centre

Transitional cell carcinoma

Recruiting

Adjuvant Datopotamab Deruxtecan with Drug Combination in Patients with High‑Risk Muscle‑Invasive Urothelial Carcinoma

Registered drugNo placebo

Adjuvant Datopotamab Deruxtecan with Drug Combination in Patients with High‑Risk Muscle‑Invasive Urothelial Carcinoma

Registered drugNo placebo

Poland

Participants:18–64 years
Substances:Durvalumab
Sponsor:AstraZeneca AB

Contact Research Centre

Polycythaemia vera

Recruiting

A Phase 3 Study of Sapablursen Compared with Placebo in Adults with Polycythemia Vera

Investigational

A Phase 3 Study of Sapablursen Compared with Placebo in Adults with Polycythemia Vera

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Sapablursen
Sponsor:Deciphera Pharmaceuticals Inc.

Contact Research Centre

Heart failure with preserved ejection fraction

Recruiting

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:AZD5004
Sponsor:AstraZeneca AB

Contact Research Centre

Atrial fibrillation

Recruiting

Safety and Pharmacodynamics of RBD4059 and Apixaban in Patients with Non‑Valvular Atrial Fibrillation: A Randomized Active‑Controlled Study

Registered drug

Safety and Pharmacodynamics of RBD4059 and Apixaban in Patients with Non‑Valvular Atrial Fibrillation: A Randomized Active‑Controlled Study

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Ribocure Pharmaceuticals AB

Contact Research Centre

Mantle cell lymphoma

Recruiting

Phase 3 Study of Orelabrutinib with Rituximab and Bendamustine vs. Rituximab and Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma Patients

Registered drug

Phase 3 Study of Orelabrutinib with Rituximab and Bendamustine vs. Rituximab and Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma Patients

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Rituximab

Contact Research Centre

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Ruxolitinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Myasthenia gravis

Recruiting

AUR200 for Patients with Generalized Myasthenia Gravis

Registered drug

AUR200 for Patients with Generalized Myasthenia Gravis

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:AUR200

Contact Research Centre

Renal cell carcinoma

Recruiting

Belzutifan and Zanzalintinib in Adults with Advanced Renal Cell Carcinoma After PD-1/L1 and VEGF-TKI Therapy

Registered drug

Belzutifan and Zanzalintinib in Adults with Advanced Renal Cell Carcinoma After PD-1/L1 and VEGF-TKI Therapy

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Belzutifan
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites